Study #2024-0052
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of single ascending doses of SBT777101 in subjects with Hidradenitis Suppurativa
MD Anderson Study Status
Enrolling
Treatment Agent
SBT777101
Description
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hidradenitis Suppurativa
Study phase:
Phase I
Physician name:
Omar Pacha
Department:
Dermatology
For general questions about clinical trials:
1-866-671-2559
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.